Lisa Firenze


  • Co-Chair, Capital Markets

Lisa Firenze has a broad-based practice focused on corporate transactions and securities law matters. She has extensive experience representing both issuers and underwriters on all aspects of public and private securities offerings, including initial public offerings, follow-on equity and debt offerings, private placements, spin-offs, convertible note deals, and SPAC transactions. Ms. Firenze also represents emerging companies and financial and other investors in venture financings, strategic investments and other corporate transactions. In addition, Ms. Firenze's practice encompasses regulatory matters arising under the federal and state securities laws, as well as securities regulatory organizations and exchanges, including the SEC, FINRA, the New York Stock Exchange and Nasdaq. Ms. Firenze also advises on a wide range of corporate governance and compliance issues.

Prior to joining WilmerHale, Ms. Firenze served as executive director and senior counsel at UBS Investment Bank. In her role at UBS, Ms. Firenze provided senior legal support to business management across all industry sectors for securities offerings and capital markets transactions, as well as a wide range of other investment banking matters, including mergers and acquisitions, liability management transactions, closed-end funds and corporate restructuring transactions, in addition to advising on general securities law matters and risk management issues.

Professional Activities

Ms. Firenze has been a frequent speaker at securities law presentations and industry conferences, including the Practicing Law Institute's “How to Prepare an Initial Public Offering” and the New York City Bar Association's “Securities Offering Process: The Basics and Beyond.” She is also an active member of the New York City Bar Association's Securities Regulation Committee. In addition, Ms. Firenze is a former member of the Corporate Financing Committee of FINRA and has served on the Capital Markets Subcommittee of the Securities Industry and Financial Markets Association (SIFMA), as well as the Financial Reporting Committee of the New York City Bar Association. Ms. Firenze is also an active member of the firm's Women's Leadership Initiative.


  • IPOs

    Initial public offerings representing either the issuer or underwriters, including the following: Adaptimmune Limited, Amylyx, Arcellx, Biotie Therapies, Candel Therapeutics, CinCor, Entasis Therapeutics, Forma Therapeutics, Graybug, Kymera Therapeutics, Icosavax, Ikena Oncology, MacroGenics, Milestone Pharmaceuticals, Oncorus, Rallybio, Rhythm Pharmaceuticals, TCR² Therapeutics, Theseus Pharmaceuticals, Xeris Pharmaceuticals and Zynerba Pharmaceuticals.

  • Public Offerings

    Numerous follow-on and other public equity and debt offerings representing either the issuer or underwriters, including offerings for the following: Accuray, ADMA Biologics, Alnylam Pharmaceuticals, Ampio Pharmaceuticals, Amylyx, Arcellx, Avadel Pharmaceuticals, BioXcel Therapeutics, Cerecor, Concert Pharmaceuticals, Curis Pharmaceuticals, CytoSorbents, Disc Medicine, Forma Therapeutics, Genpact, Ikena Oncology, Infinity Pharmaceuticals, Inovio Pharmaceuticals, Kymera Therapeutics, MacroGenics, The Medicines Company, Milestone Pharmaceuticals, Oncorus, Progenics Pharmaceuticals, Sensata, State Street, Synergy Pharmaceuticals, Viridian Therapeutics, Xeris Pharmaceuticals and Zynerba Pharmaceuticals.
  • Strategic and Venture Financings

    Strategic and venture financings, representing either the company or investors, including financings for the following: BlueVine, Capitolis, Checkbook, Cool Planet, Crux Informatics, Inpher, Ionic Security, Kensho Technologies, MerQube, Natural Capital Exchange, Persado, ReversingLabs, Saphyre, Taulia, Toast, Transfr, Ursa Space Systems, Volley Labs and WeConvene.


Insights & News


  • Education

    • JD, Columbia Law School

      Harlan Fiske Stone Scholar
    • BA, Yale University

      magna cum laude
  • Admissions

    • New York

    • Connecticut



Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.